AbbVie Reports meta-analysis Data for Pegcetacoplan in Thyroid cancer

AbbVie today announced meta-analysis results for Pegcetacoplan in patients with Thyroid cancer. The study demonstrated that Pegcetacoplan provides durable benefit over long-term follow-up compared to standard of care or placebo. These results provide important insights into the treatment of Thyroid cancer and support the continued development of Pegcetacoplan in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Pegcetacoplan was consistent with previous observations, with no new safety signals identified.